Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
8.195
Zitationen
19
Autoren
2009
Jahr
Abstract
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.)
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 28.787 Zit.
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 · 15.677 Zit.
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.638 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.441 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.871 Zit.
Autoren
Institutionen
- Chinese University of Hong Kong(CN)
- Chiang Mai University(TH)
- Maharaj Nakorn Chiang Mai Hospital(TH)
- National Taiwan University Hospital(TW)
- Chinese Academy of Medical Sciences & Peking Union Medical College(CN)
- National Cancer Center Hospital East(JP)
- Prince of Songkla University(TH)
- Shanghai Chest Hospital(CN)
- Universitas Dr. Soetomo(ID)
- National Hospital Organization Kyushu Cancer Center(JP)
- Tokyo National Hospital(JP)
- Guangdong General Hospital(CN)
- AstraZeneca (Japan)(JP)
- AstraZeneca (United Kingdom)(GB)
- Kindai University(JP)